57 results about "Cytotoxic Brain Edema" patented technology

Provided are methods for treatment of pathological conditions causing hemolysis, cerebral edema, acute kidney injury and non-anaphylactic shock, including envenomation, trauma, cerebral malaria and mast-cell diseases using at least one PLA2 inhibitor, alone or in combination with other agents. The unexpected versatility of PLA2 inhibitors, their dosage forms and combinations make them candidates as essential medicines for the developing world.

A method of treating or preventing adverse outcomes associated with tissue plasminogen activator (tPA) administration, cerebral edema-related side effects, cerebral edema associated with radiation therapy, or migraine headaches by administering an effective amount of a SUR1-TRPM4 channel inhibitor, such as glyburide, and optionally the co-administration of a second therapeutically active agent, to a subject in need thereof. Adverse outcomes associated with tPA include cerebral hemorrhage, cerebral edema, physical impairment or death. The administration of the SUR1-TRPM4 channel inhibitors occurs prior to the radiation therapy, during the radiation therapy, after the radiation therapy, or combinations thereof. The SUR1-TRPM4 channel inhibitor is administered prior to surgical excision of a brain tumor, CAR-T therapy, or administration of flutarabine. Alternatively, or in addition, the SUR1-TRPM4 channel inhibitor is administered prior the onset of the cerebral edema-related side effects.

This invention discloses a data processing method and system based on the changing trends of image features, relating to the field of cerebral infarction early warning technology. The data processing method includes: feature extraction: processing image data and modal data separately using feature analysis methods to obtain image features, image feature change data, modal data features, modal data feature change data, and the regions where the features are located. In this invention, image data provides intuitive information about brain structure and lesions, while modal data supplements key features such as hemodynamics, brain tissue electrical activity, and electrical impedance from different physiological dimensions. TCD data can monitor blood flow velocity and vascular resistance in real time, BI data is sensitive to changes in pathological states such as cerebral edema, and EEG data reflects subtle changes in neuronal electrical activity. Through feature extraction and analysis, the combination of multi-source heterogeneous data achieves the correction of image feature changing trends, thereby ensuring the accuracy of data processing.

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The present invention discloses a preparation method of rhein / berberine / glycyrrhizic acid hydrogel, which comprises the following steps: dispersing the rhein / berberine nanoparticle solution, glycyrrhizic acid and PBS solution uniformly, and standing to obtain the rhein / berberine / glycyrrhizic acid hydrogel; the concentration of glycyrrhizic acid in the hydrogel is 0.01-0.04 g / mL. The rhein / berberine / glycyrrhizic acid hydrogel prepared by the present invention has the characteristics of anti-inflammation, reducing edema, neuroprotection, etc., solves the limitation of poor curative effect of single-component drugs, realizes in-situ injection administration of three small-molecule drugs, and has synergistic effect, and is applied in drugs for treating inflammatory or edematous encephalopathy accompanied by traumatic brain injury, cerebral edema, Alzheimer's disease, Parkinson's disease, etc., and has obvious therapeutic effect.

The invention relates to the technical field of biological medicine, and particularly discloses a macrophage membrane coated plateau encephaledema drug carrier and a preparation method and application thereof, and the macrophage membrane coated plateau encephaledema drug carrier is composed of a nanoparticle core and a macrophage membrane shell layer wrapping the core; the nanoparticle core comprises an ROS-responsive carrier material and carbon monoxide release molecules MnCO entrapped in the ROS-responsive carrier material; the content of phosphatidylserine in the shell layer of the macrophage membrane is not less than 5 mol% of the total phospholipid of the membrane. According to the invention, a bionic delivery system of ROS response type MnCO nanoparticles coated with a macrophage membrane is constructed, phosphatidylserine on the surface of the membrane is utilized to actively activate a microglial cell Trem2 receptor, a positive feedback cycle of targeting phagocytosis-CO release-Trem2 up-regulation is formed, and at the same time, fatty acid oxidative metabolism reprogramming is promoted by means of degraded membrane lipid, so that the biomimetic delivery system is used for preparing the ROS response type MnCO nanoparticles. And multi-mechanism synergistic efficient brain-targeted therapy is realized.

To provide a compound which can be used for prevention, treatment and control of aquaporin-mediated conditions such as diseases of water imbalance, for example, cerebral edema, a pharmaceutical composition, and a method for producing the same.SOLUTION: There is provided a hydrate of 2 - {[3, 5-bis (trifluoromethyl) phenyl] carbamoyl} - 4-chlorophenyl dihydrogen phosphate represented by the following structure, which exhibits an XRPD pattern comprising at least five 2 θ (°) values selected from the group consisting of 8.8, 9.5, 11.1, 15.2, 15.5, 16.4, 20.2, 20.6, 23.6, 24.0, 24.9 and 27.2, wherein the XRPD is measured using an incident beam of CuK α radiation of 1.54059 Å.SELECTED DRAWING: None

This invention relates to animal models and their applications, specifically to a method for constructing a spontaneous mouse cerebral edema model and its application. This invention utilizes PEN2... fl / + Mice and PEN2 fl / + Mice were mated to obtain PEN2. fl / fl Homozygous mice; then the obtained PEN2 fl / fl Mice and hGFAP Cre / + Mice were mated to obtain PEN2. fl / + hGFAP Cre / + Mice; the final PEN2 obtained fl / + hGFAP Cre / + Mice and PEN2 fl / fl Mice were mated to obtain PEN2. fl / fl hGFAP Cre / + The mouse model is a spontaneous mouse cerebral edema model. In this model, PEN2 protein levels are significantly downregulated, and the mouse exhibits a severe cerebral edema phenotype. This model can be used to establish a cerebral edema drug screening platform. It can also be used for research on cerebral edema-related diseases, such as the pathogenesis of cerebral edema caused by infection, glioma, and traumatic brain injury, as well as for the development of technologies and products for the diagnosis and treatment of related diseases.

The invention belongs to the technical field of biological medicines, and relates to a high-throughput screening method based on cell membrane nano-vesicles and application of a screened drug afloqualone in resisting encephaledema. Through a screening model, it is surprisingly found that the drug afloqualone AFQ on the market has the remarkable effect of inhibiting water inflow and encephaledema. The glibenclamide pharmaceutical composition shows a curative effect superior to that of glibenclamide in an animal model, can effectively reduce the volume of cerebral infarction, reduce the death rate in an acute stage and improve neurological impairment, and is known to have good clinical safety and good clinical application prospects. The invention provides a brand-new treatment strategy with a great clinical application prospect for solving the problem of lack of effective medicines for post-stroke encephaledema at present.

The present invention provides the use of α-asarone in the preparation of a drug for preventing or treating hemorrhagic stroke. The structure of α-asarone is shown in Formula I. It can significantly improve short-term neurological deficits and long-term learning and memory function in model rats, reduce cerebral edema, improve blood-brain barrier permeability, and prevent or alleviate brain tissue atrophy during the recovery period. It has a definite therapeutic effect on animal models of hemorrhagic stroke without significant toxic side effects, and is expected to become a promising drug for the prevention and treatment of hemorrhagic stroke. #imgabs0#

The application relates to application of a furan coumarin compound shown in a formula I to prevention and / or treatment of a nervous system disease related to neuroinflammation. The furan coumarin compound has a protective effect on normoxia + lipopolysaccharide (LPS) and hypoxia + LPS combined induction of mouse stellate glial C8-D1A cell normoxia and hypoxia neuroinflammation models, can promote cell growth, inhibit production of related inflammatory factors, effectively reduce brain water content production, weight loss and key protein expression of a plateau cerebral edema model mouse, and can be developed into a medicine for preventing and / or treating neuroinflammation related diseases.

The invention belongs to the technical field of gene drugs, and particularly relates to application of lncRNA-AU020206 in preparation of drugs for treating cerebral arterial thrombosis, the key effect of the lncRNA-AU020206 in occurrence and development of the cerebral arterial thrombosis is disclosed for the first time, and it is clear that the lncRNA-AU020206 activates ferroptosis signal channels through negative regulation of SLC7A11 expression, so that cerebral ischemia reperfusion injury is aggravated. In-vivo and in-vitro experiments prove that the levels of MDA, ROS and Fe < 2 + > can be remarkably reduced by silencing the lncRNA-AU020206, the expression of GPX4 and SLC7A11 can be up-regulated, the cerebral infarction volume and neurological dysfunction can be reduced, and cerebral edema and apoptosis can be improved. Therefore, the lncRNA-AU020206 not only can be used as a new target for treating the cerebral arterial thrombosis, but also can be used for developing a related diagnostic kit, and has remarkable clinical application prospect and market value.

The invention belongs to the technical field of biological medicines, and provides application of sodium tyrosol sulfate and a derivative tyrosol compound in preparation of brain health products. The structure of the sodium tyrosol sulfate and the derivative tyrosol compound is shown as a formula I. The sodium tyrosol sulfate and the derivative tyrosol compound can effectively reduce the infarction area after cerebral ischemia and relieve encephaledema caused by cerebral ischemia, and have wide application in the aspects of resisting cerebral ischemia and improving encephaledema and cerebral infarction caused by cerebral ischemia. Meanwhile, learning and memory abilities can be effectively improved, brain function recovery is promoted, and the traditional Chinese medicine composition can be widely applied to treatment of behavior / cognitive dysfunction diseases such as cerebral trauma, cerebrovascular accidents, Alzheimer's disease and Parkinson's disease. And the formula I of the # imgabs0 # is shown in the specification.

The application discloses application of a 2-amino-pyrazine derivative in preparation of a medicine for treating and / or preventing apoplexy and complications, wherein the 2-amino-pyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl]oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,6-dimethylbenzamide; the apoplexy is acute ischemic stroke; and the 2-amino-pyrazine derivative can be used as an active ingredient in a medicine for treating and / or preventing post-stroke brain injury and complications, effectively reducing post-stroke cerebral infarction volume, improving sensory-motor and balance nerve functions, and preventing and treating post-stroke complications such as cerebral edema and acute lung injury.

The present invention discloses the use of a compound in the preparation of a medicament for treating and / or preventing stroke. The compound is 2,3-dihydronaphtho[1,2-b]furan-4,5-dione, and the stroke includes acute ischemic stroke or ischemic reperfusion brain injury. The compound can effectively treat or prevent acute ischemic stroke by alleviating the acute brain injury caused by acute ischemic stroke or ischemic reperfusion, reducing the volume of cerebral infarction after acute ischemic stroke, alleviating cerebral edema after stroke, and improving neurological function after stroke.

The invention belongs to the technical field of nursing vests, and discloses a multi-mode vital sign intelligent nursing vest which comprises a front vest, and a patch opening is formed in the front face of the front vest. By arranging the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, due to the design of the respiration sensor, the electrocardio sensor, the body temperature sensor and the muscular tension sensor, respiration, electrocardio, body temperature and muscular tension of a patient can be monitored in real time, and monitored data are transmitted to the single chip microcomputer; the single-chip microcomputer monitors vital signs and neurological function changes of a patient in real time through an AI algorithm, automatically warns the risk of encephaledema, epileptic seizure or reperfusion injury, and transmits the monitored vital signs and neurological function changes of the patient to the medical system through the data transmission module. Meanwhile, when it is monitored that the vital signs and the neurological functions of the patient are abnormal, an alarm is given out through the alarm to remind medical staff.

A method for identifying a cerebral edema or a cerebral microhemorrhage in a subject, the method including providing a sample obtained from the subject, comprising a level of one or more biomarkers, wherein the one or more biomarkers comprises one or more GLX-related GAGs, one or more GLX-related PGs, one or more GLX-related GPs, one or more GLX-related GLs, one or more GLX-related GCs, or one or more fragments thereof, or any combination of the aforementioned biomarkers; measuring or detecting the level of the one or more biomarkers in the sample; comparing the level of the one or more biomarkers measured or detected to a reference level for the one or more biomarkers; and identifying the subject as having a cerebral edema or a cerebral microhemorrhage if the level of the one or more of the biomarkers measured or detected from the sample are different than the reference level for the one or more biomarkers.

The application discloses application of a MAC-1 agonist in preparation of a medicine for treating and / or relieving cerebral hemorrhage. Specifically disclosed is the use of Leukadherin-1 (LA-1) or a pharmaceutically acceptable salt, isomer or derivative thereof in preparation of a medicine for treating cerebral hemorrhage and secondary brain injury thereof. The medicine can inhibit the migration of immune cells across the blood-brain barrier, reduce cerebral edema, promote hematoma absorption and reduce neural inflammation by regulating the MAC-1-mediated immune adhesion signal pathway, thereby exerting a neuroprotective effect. Meanwhile, a pharmaceutical composition containing the MAC-1 agonist is provided. The application provides a new target and a drug development strategy for cerebral hemorrhage treatment.

The invention relates to the technical field of traditional Chinese medicines, and discloses application of donkey-hide gelatin bone-strengthening oral liquid in prevention and treatment of plateau hypoxic polycythemia. The colla corii asini bone-strengthening oral liquid can be used for preparing medicines for reducing the number of red blood cells in the high altitude polycythemia, improving the form and function of the red blood cells in the high altitude polycythemia and improving pulmonary edema and encephaledema caused by the high altitude polycythemia. The colla corii asini bone-strengthening oral liquid is applied to prevention and treatment of the plateau hypoxic polycythemia, and the problems that at present, traditional Chinese medicine formulas for treating the plateau polycythemia clinically are few, and the plateau polycythemia resisting effect is poor can be solved.

This invention discloses a system and apparatus for constructing an animal model of high-altitude cerebral edema (HACE). The resulting animal model successfully simulates the cognitive impairment and neuroinflammatory response associated with HACE, effectively reproducing key pathological features of HACE, such as oxidative stress, neuroinflammation, and neurological impairment. This model can be used to study the pathogenesis, early diagnosis, and potential treatment strategies for HACE. This invention provides a reliable animal model for experimental research and drug screening of HACE-related diseases.

Provided in the present disclosure is the use of edaravone and a pharmaceutically acceptable salt thereof in the prevention and / or treatment of acute high-altitude illnesses caused by acute high-altitude hypobaric hypoxia. The acute high-altitude illnesses include, for example, acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE). Additionally provided in the present disclosure is the use of edaravone and a pharmaceutically acceptable salt thereof in the prevention and / or treatment of high-altitude pulmonary hypertension (HAPH) and inflammatory responses caused by acute high-altitude hypobaric hypoxia.

This invention discloses a method and system for predicting the risk of malignant cerebral edema after mechanical thrombectomy in ischemic stroke, aiming to address the pain points of existing prediction tools, such as insufficient accuracy, lack of clinical interpretability, and difficulty in directly supporting decision-making. The core solution involves: stably extracting key predictive variables from multi-source clinical and laboratory data through a multi-algorithm consensus feature selection mechanism (LASSO, Boruta algorithm); employing eight machine learning algorithms to select the best high-performance prediction model, and using repeated cross-validation and grid search for robust optimization; innovatively and deeply integrating the SHAP interpretability framework to achieve global, local, and individualized interpretation of the model predictions; and finally deploying it as an integrated clinical decision support system, outputting a visual report that combines risk probability, risk classification, and decision-making basis. This method significantly improves the early risk identification capability of malignant cerebral edema, and the model exhibits excellent discrimination and calibration.

This disclosure provides medicaments and methods for treating envenomation using small molecule inhibitors of secretory phospholipase A2 (sPLA2). The sPLA2 inhibitor AZD2716 and related compounds can be used as monotherapy. Alternatively, the sPLA2 inhibitor varespladib and / or methyl varespladib can be used in combination with a statin. When a subject has been envenomed (for example, by a snake bite or bee sting), the medicaments can be administered to prevent lethal effects or tissues damage cause by the venom: for example, acute kidney injury, mast cell degranulation, or cerebral edema. The medicaments may be contained in an automatic injection device or an injection pen to deliver an effective dose as soon as possible following envenomation.

The present invention discloses a method for improving the quality of image reconstruction during the treatment of cerebral edema. First, by determining the linear relationship between the change in the measured boundary voltage and the degree of dehydration, and then combining with the prior matrix to select the change in the measured boundary voltage caused solely by the scalp corresponding to the degree of dehydration, the image reconstruction of the intracranial dehydration region is achieved by suppressing the influence of scalp dehydration. The method proposed by the present invention can effectively improve the spatial resolution of the reconstructed image, thereby improving the imaging quality, and has a wide range of applicability and great application potential in electrical impedance tomography of the brain.

The invention discloses a bioengineering apoptotic body based on apoptotic body membrane protein and lipidosome as well as a preparation method and application of the bioengineering apoptotic body. The bioengineered apoptotic body is formed by chimeric combination of apoptotic body membrane protein and liposome loaded with gastrodin and Cy5. The bioengineered apoptotic body for simulating the natural apoptosis process of the mesenchymal stem cells is constructed, microglial cells can be promoted to be polarized to an M2 type, anti-inflammatory factors and neurotrophic factors are released, neuronal proliferation is promoted, the cell oxidation resistance is improved, the neuromotor function is improved, and encephaledema is relieved, so that traumatic brain injury is effectively treated.

The invention provides a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating cerebral arterial thrombosis, and relates to the technical field of biological medicine. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 5-30 parts of Yulangsan, 5-30 parts of panax japonicus, 5-30 parts of ruta graveolens, 5-30 parts of camphorwood, 5-30 parts of millettia japonica, 5-30 parts of costus root, 5-30 parts of rhizoma curculiginis, 5-30 parts of clinopodium herb, 5-30 parts of white hyacinth bean and 5-30 parts of radix puerariae. The whole formula treats both qi and blood, regulates phlegm and blood stasis, is reasonable in compatibility of the medicines, and has the effects of tonifying qi and activating blood, dispersing blood stasis and dredging collaterals, clearing heat and dissipating blood stasis, restoring consciousness and dredging collaterals, and tonifying spleen and warming kidney. The traditional Chinese medicine composition can relieve cerebral infarction and encephaledema, improve neurological dysfunction, inhibit neuronal apoptosis and regulate inflammatory response to relieve inflammatory damage of brain tissue, and a good treatment effect on cerebral arterial thrombosis model rats is achieved. The traditional Chinese medicine composition provides a new choice for development of medicines for treating cerebral arterial thrombosis.

The invention discloses an application of a 2-aminopyrazine derivative in preparation of a medicine for treating and / or preventing cerebral apoplexy and complications, and the 2-aminopyrazine derivative iMAP4K1 is (R)-4-[5-amino-6-[[1-(1-methyl-4-piperidyl)-4-pyrazolyl] oxy]-2-pyrazinyl]-N-[2-(3-fluoro-1-pyrrolidinyl) ethyl]-2, 6-dimethylbenzamide; the cerebral apoplexy is acute ischemic apoplexy; the 2-aminopyrazine derivative can be used as an active component, is applied to drugs for treating and / or preventing cerebral injury and complications after stroke, effectively reduces the volume of cerebral infarction after stroke, improves sensory motility, balances neurological functions, and prevents and treats cerebral edema and acute lung injury which are complications after stroke.

4-alkoxy-substituted 2,6-dihydroxybenzoic acid ester compound of d-camphor or fenchol, the structure conforms to general formula (I) wherein: R 1 is or R 2 is -H, -NO2; R 3 alkyl of 1-4 carbon atoms or the compound has good anti-inflammatory effect, and can be used for preparing drugs for treating inflammation-related diseases or stroke injury, cerebral edema, senile dementia.

The present application provides a mannitol injection and its production method, the key lies in improving the solubility and stability of mannitol, and enhancing the safety and effectiveness of the final product. The specific steps include: first, mannitol is mixed with cyclodextrin in a certain proportion to form a complex through freeze-drying technology, thereby improving the stability of the solution; then, adding appropriate amount of electrolyte and acid-base regulator to adjust the pH value, to optimize the physiological compatibility and reduce local irritation; then, through the double filtration system to ensure the purity and sterility of the solution; finally, using high temperature sterilization to ensure the sterility of the product. This series of processes not only improves the bioavailability of mannitol injection, but also significantly reduces the complexity and risk caused by crystal precipitation, making the product more suitable for wide application in the medical field, such as treating cerebral edema or reducing intracranial pressure.

The present invention relates to the technical field of biomedicine, and in particular to a sulfonamide compound for therapeutic use, an enantiomer thereof, a preparation method, and uses. The present invention provides the following beneficial effects: the provided sulfonamide compound and the enantiomer thereof have the characteristics of high stability, a prolonged duration of action, superior efficacy, and the like, thereby serving as a superior diuretic and a novel anti-cerebral edema drug.